HK1129890A1 - C-met protein kinase inhibitors for the treatment of proliferative disorders - Google Patents
C-met protein kinase inhibitors for the treatment of proliferative disordersInfo
- Publication number
- HK1129890A1 HK1129890A1 HK09107689.2A HK09107689A HK1129890A1 HK 1129890 A1 HK1129890 A1 HK 1129890A1 HK 09107689 A HK09107689 A HK 09107689A HK 1129890 A1 HK1129890 A1 HK 1129890A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- protein kinase
- kinase inhibitors
- proliferative disorders
- met protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78493706P | 2006-03-22 | 2006-03-22 | |
US87597306P | 2006-12-20 | 2006-12-20 | |
PCT/US2007/007016 WO2007111904A2 (en) | 2006-03-22 | 2007-03-21 | C-met protein kinase inhibitors for the treatment of proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129890A1 true HK1129890A1 (en) | 2009-12-11 |
Family
ID=38372386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107689.2A HK1129890A1 (en) | 2006-03-22 | 2009-08-21 | C-met protein kinase inhibitors for the treatment of proliferative disorders |
Country Status (20)
Country | Link |
---|---|
US (2) | US7872031B2 (xx) |
EP (1) | EP2004625B1 (xx) |
JP (2) | JP2009533327A (xx) |
KR (1) | KR20090007347A (xx) |
CN (1) | CN101479255B (xx) |
AR (1) | AR060054A1 (xx) |
AT (1) | ATE453635T1 (xx) |
AU (1) | AU2007231577B2 (xx) |
CA (1) | CA2646701A1 (xx) |
CL (1) | CL2007000752A1 (xx) |
DE (1) | DE602007004092D1 (xx) |
ES (1) | ES2336625T3 (xx) |
HK (1) | HK1129890A1 (xx) |
IL (1) | IL194242A0 (xx) |
MX (1) | MX2008012096A (xx) |
NO (1) | NO20084435L (xx) |
NZ (1) | NZ571933A (xx) |
RU (1) | RU2008141761A (xx) |
TW (1) | TW200806646A (xx) |
WO (1) | WO2007111904A2 (xx) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
MX2009002229A (es) | 2006-09-08 | 2009-03-16 | Hoffmann La Roche | Benzotriazoles como moduladores de cinasas. |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US7592342B2 (en) * | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
EP2173722B1 (en) * | 2007-07-26 | 2012-08-29 | Novartis AG | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
CA2701124A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
CA2703653A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives -083 |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
KR101034351B1 (ko) * | 2008-05-14 | 2011-05-16 | 한국화학연구원 | 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물 |
EP2350045A1 (en) * | 2008-10-21 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
CN102264721B (zh) * | 2008-11-10 | 2015-12-09 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的化合物 |
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
US20130035326A1 (en) * | 2009-08-19 | 2013-02-07 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
EP2473513B1 (en) * | 2009-09-03 | 2019-06-05 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
KR101692126B1 (ko) * | 2009-12-18 | 2017-01-02 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 항혈소판약 |
ES2531109T3 (es) * | 2009-12-30 | 2015-03-10 | Arqule Inc | Compuestos de imidazopiridinil-aminopiridina |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
NZ603477A (en) * | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
EP2569284B1 (en) * | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
AU2011270807A1 (en) | 2010-06-23 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase |
US9403815B2 (en) | 2010-06-24 | 2016-08-02 | The Regents Of The University Of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
KR20140027974A (ko) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Tra 키나제의 억제제로서 유용한 아미노피라진 화합물 |
FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
JP5959330B2 (ja) * | 2011-06-17 | 2016-08-02 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
JP6046710B2 (ja) | 2011-06-24 | 2016-12-21 | アーキュール,インコーポレイティド | 置換されたイミダゾピリジニル−アミノピリジン化合物 |
US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
WO2012178038A1 (en) | 2011-06-24 | 2012-12-27 | The Broad Institute, Inc. | Methods of treating cancer |
CA2842841C (en) * | 2011-07-27 | 2016-04-19 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
ES2899880T3 (es) | 2011-09-30 | 2022-03-15 | Vertex Pharma | Tratamiento de cáncer de páncreas y cáncer de pulmón de células no pequeñas con inhibidores de ATR |
AU2012315611A1 (en) | 2011-09-30 | 2014-04-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) * | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
CN103204844A (zh) * | 2012-01-17 | 2013-07-17 | 上海艾力斯医药科技有限公司 | 氨基杂芳基化合物及其制备方法与应用 |
US9815831B2 (en) | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
IN2014KN02410A (xx) | 2012-04-05 | 2015-05-01 | Vertex Pharma | |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP3418281B1 (en) | 2012-12-07 | 2020-09-30 | Vertex Pharmaceuticals Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
JP6284949B2 (ja) * | 2013-01-02 | 2018-02-28 | ハー・ルンドベック・アクチエゼルスカベット | Lrrk2阻害剤としてのアミノピリジン誘導化合物 |
ES2608395T3 (es) | 2013-01-23 | 2017-04-10 | Astrazeneca Ab | Compuestos químicos |
EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
EP2970311A4 (en) | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | BMP INHIBITORS AND METHODS OF USE |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
CN110156770B (zh) * | 2013-11-27 | 2022-10-04 | 圣诺康生命科学公司 | 作为tam族激酶抑制剂的氨基吡啶衍生物 |
MX370390B (es) | 2013-12-06 | 2019-12-11 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. |
CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
MX367267B (es) * | 2014-03-24 | 2019-08-12 | Arqule Inc | Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h -imidazo[4,5-b]piridin-2-il)piridin-2-amina. |
JP2017514793A (ja) * | 2014-03-26 | 2017-06-08 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Bmp阻害用組成物及びbmp阻害方法 |
HUE046150T2 (hu) * | 2014-04-22 | 2020-02-28 | Arqule Inc | Helyettesített imidazopiridinil-amino-piridin vegyületek sói és polimorf formái |
CN106458966B (zh) | 2014-04-24 | 2019-05-07 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物 |
CN106458980A (zh) | 2014-04-24 | 2017-02-22 | 诺华股份有限公司 | 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
CN110590787A (zh) | 2014-06-05 | 2019-12-20 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
CN105315287A (zh) * | 2014-08-04 | 2016-02-10 | 杭州沙力医药科技有限公司 | 一种单n-叔丁氧羰基-2,6-双氮杂螺[3,3]庚烷盐酸盐的合成方法 |
WO2016054406A1 (en) * | 2014-10-01 | 2016-04-07 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
BR112017009010A2 (pt) | 2014-10-31 | 2017-12-26 | Massachusetts Gen Hospital | moduladores potentes de gama-secretase |
MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN105061405A (zh) * | 2015-08-04 | 2015-11-18 | 合肥创新医药技术有限公司 | 非马沙坦钾盐三水合物的制备方法 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
MX2020009228A (es) | 2018-03-08 | 2021-01-08 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. |
CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
US20220127249A1 (en) * | 2019-02-22 | 2022-04-28 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN111116585B (zh) * | 2019-12-31 | 2021-02-05 | 北京鑫开元医药科技有限公司 | 具有c-MET激酶抑制活性化合物、制备方法、组合物及用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
CN112409337A (zh) * | 2020-12-21 | 2021-02-26 | 李寒 | 一种取代的吡嗪衍生物及其用途 |
CN112341437A (zh) * | 2020-12-21 | 2021-02-09 | 李寒 | 一种取代的吡嗪衍生物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2114A (en) * | 2003-02-26 | 2010-03-04 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
WO2005040345A2 (en) * | 2003-09-24 | 2005-05-06 | Vertex Pharmceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
US7169781B2 (en) * | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
RS51362B (en) * | 2004-08-26 | 2011-02-28 | Pfizer Inc. | ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
-
2007
- 2007-03-21 WO PCT/US2007/007016 patent/WO2007111904A2/en active Application Filing
- 2007-03-21 NZ NZ571933A patent/NZ571933A/en not_active IP Right Cessation
- 2007-03-21 JP JP2009501540A patent/JP2009533327A/ja active Pending
- 2007-03-21 RU RU2008141761/04A patent/RU2008141761A/ru not_active Application Discontinuation
- 2007-03-21 DE DE602007004092T patent/DE602007004092D1/de active Active
- 2007-03-21 AT AT07753626T patent/ATE453635T1/de not_active IP Right Cessation
- 2007-03-21 MX MX2008012096A patent/MX2008012096A/es active IP Right Grant
- 2007-03-21 ES ES07753626T patent/ES2336625T3/es active Active
- 2007-03-21 CN CN2007800182084A patent/CN101479255B/zh not_active Expired - Fee Related
- 2007-03-21 EP EP07753626A patent/EP2004625B1/en not_active Not-in-force
- 2007-03-21 US US11/726,170 patent/US7872031B2/en not_active Expired - Fee Related
- 2007-03-21 CA CA002646701A patent/CA2646701A1/en not_active Abandoned
- 2007-03-21 AU AU2007231577A patent/AU2007231577B2/en not_active Expired - Fee Related
- 2007-03-21 KR KR1020087025755A patent/KR20090007347A/ko not_active Application Discontinuation
- 2007-03-22 AR ARP070101171A patent/AR060054A1/es unknown
- 2007-03-22 TW TW096109881A patent/TW200806646A/zh unknown
- 2007-03-22 CL CL200700752A patent/CL2007000752A1/es unknown
-
2008
- 2008-09-22 IL IL194242A patent/IL194242A0/en unknown
- 2008-10-22 NO NO20084435A patent/NO20084435L/no not_active Application Discontinuation
-
2009
- 2009-08-21 HK HK09107689.2A patent/HK1129890A1/xx not_active IP Right Cessation
-
2010
- 2010-11-09 US US12/942,395 patent/US8232406B2/en not_active Expired - Fee Related
-
2014
- 2014-03-17 JP JP2014054013A patent/JP2014132024A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2004625A2 (en) | 2008-12-24 |
MX2008012096A (es) | 2008-12-17 |
EP2004625B1 (en) | 2009-12-30 |
US8232406B2 (en) | 2012-07-31 |
KR20090007347A (ko) | 2009-01-16 |
US7872031B2 (en) | 2011-01-18 |
CL2007000752A1 (es) | 2008-02-08 |
NO20084435L (no) | 2008-11-28 |
US20110059936A1 (en) | 2011-03-10 |
IL194242A0 (en) | 2009-08-03 |
US20070254868A1 (en) | 2007-11-01 |
DE602007004092D1 (de) | 2010-02-11 |
AR060054A1 (es) | 2008-05-21 |
ES2336625T3 (es) | 2010-04-14 |
NZ571933A (en) | 2011-06-30 |
CN101479255B (zh) | 2013-05-01 |
CA2646701A1 (en) | 2007-10-04 |
JP2014132024A (ja) | 2014-07-17 |
AU2007231577B2 (en) | 2012-07-19 |
CN101479255A (zh) | 2009-07-08 |
JP2009533327A (ja) | 2009-09-17 |
WO2007111904A2 (en) | 2007-10-04 |
RU2008141761A (ru) | 2010-04-27 |
ATE453635T1 (de) | 2010-01-15 |
AU2007231577A1 (en) | 2007-10-04 |
WO2007111904A3 (en) | 2007-12-13 |
TW200806646A (en) | 2008-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1129890A1 (en) | C-met protein kinase inhibitors for the treatment of proliferative disorders | |
EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
IL185016A0 (en) | Compounds for the treatment of proliferative disorders | |
HK1139036A1 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
IL201650A0 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
EP1981526A4 (en) | ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS | |
SI2001892T1 (sl) | Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni | |
ZA201001193B (en) | 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders | |
IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
EP1853539A4 (en) | HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES | |
SI2193133T1 (sl) | Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze | |
IL192692A0 (en) | Compounds for the treatment of inflammatory disorders | |
ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
IL195152A0 (en) | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
AU2007288337A8 (en) | Compounds for treating proliferative disorders | |
EP2139475A4 (en) | USE OF PDE7 INHIBITORS IN THE TREATMENT OF | |
HK1208701A1 (en) | Means for inhibiting the expression of protein kinase | |
IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
IL184997A0 (en) | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis | |
EP2164517A4 (en) | IL-18 AND PROTEIN KINASE-R INHIBITION FOR THE TREATMENT OF COPD | |
GB0604780D0 (en) | Use of substituted piperazine compounds for the treatment of food related disorders | |
ZA200704735B (en) | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis | |
GB0604782D0 (en) | Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200321 |